US2019192490A1PendingUtilityA1

Rifaximin ready-to-use suspension

76
Assignee: LUPIN LTDPriority: Mar 10, 2010Filed: Nov 26, 2018Published: Jun 27, 2019
Est. expiryMar 10, 2030(~3.7 yrs left)· nominal 20-yr term from priority
A23V 2002/00A61K 9/10A61K 31/437A23L 27/00A61K 31/428A61P 31/04
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.

Claims

exact text as granted — not AI-modified
1 ) A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). 
     
     
         2 ) The stable, taste-masked, ready-to-use suspension as of  claim 1  wherein one or more pharmaceutically acceptable additive(s) is selected from flavoring agent(s), sweetening agent(s), buffering agents(s), preservative(s), suspending agents(s), antioxidant(s), wetting agent(s), dispersing agent(s), pH stabilizing agent(s), taste enhancing agent(s), antifoaming agent(s) or mixtures thereof. 
     
     
         3 ) The stable, taste-masked, ready-to-use suspension as of  claim 1  wherein the pH of the suspension is from about 2 to about 8. 
     
     
         4 ) The stable, taste-masked, ready-to-use suspension as of  claim 1  wherein the viscosity of the suspension is from about 20 to about 200 Cps. 
     
     
         5 ) A stable taste-masked, ready-to-use suspension as of  claim 1  wherein the d90 of rifaximin is less than about 40 um. 
     
     
         6 ) A process for preparing stable, taste-masked, ready-to-use suspension of rifaximin wherein the said process comprises the steps of dispersing rifaximin in the suspension base comprising one or more pharmaceutically acceptable additive(s) and further milling the suspension to obtain a homogenously dispersed rifaximin suspension.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.